Ocugen IncChange company Symbol lookupSelect an option...OCGN Ocugen IncERAS Erasca IncMEOH Methanex CorpCADL Candel Therapeutics IncYECO Yulong Eco-Materials LtdZVOI Zovio IncYEXT Yext IncZNOG Zion Oil and Gas IncPM Philip Morris International IncAFRM Affirm Holdings IncGo
Change company Symbol lookup
Select an option...
OCGN Ocugen Inc
ERAS Erasca Inc
MEOH Methanex Corp
CADL Candel Therapeutics Inc
YECO Yulong Eco-Materials Ltd
ZVOI Zovio Inc
YEXT Yext Inc
ZNOG Zion Oil and Gas Inc
PM Philip Morris International Inc
AFRM Affirm Holdings Inc
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Small Cap Growth
Company profileOcugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings Beat Consensus (Q1 ending 03/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q1 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced May 5, 2023 | -$0.07 | Q1 Consensus of 5 analysts | -$0.11 | Difference from consensus | 35.19% | Q2 Earnings will announce | (Unconfirmed) August 3, 2023 |
Quarterly Earnings History and Estimates
Hide high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
OCGN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.